Renin News and Research

RSS

Renin, also known as angiotensinogenase, is an enzyme that participates in the body's renin-angiotensin system (RAS) that mediates extracellular volume (i.e., that of the blood plasma, lymph and interstitial fluid), and arterial vasoconstriction. Thus, it regulates the body's mean arterial blood pressure.

Ground-breaking study into causes of high blood pressure

A researcher from the University of Leicester's Department of Cardiovascular Sciences has been involved in a ground-breaking study into the causes of high blood pressure.

9 Nov 2011

Data from Concert Pharmaceuticals' CTP-499 study to be presented at ASN Kidney Week 2011

Concert Pharmaceuticals, Inc. today announced that three abstracts relating to CTP-499, its clinical candidate for the potential treatment of diabetic nephropathy, have been accepted for poster presentations at the American Society of Nephrology's (ASN) Kidney Week 2011.

19 Oct 2011

Hypertension drugs might reduce occurrence of Alzheimer's

Within the next 20 years it is expected the number of people with Alzheimer's disease (AD) will double from its current figure of half a million to one million. A new study has looked at whether certain types of drugs used to treat high blood pressure, also called hypertension, might have beneficial effects in reducing the number of new cases of Alzheimer's disease each year.

18 Oct 2011

Spinifex announces new data from EMA401 pre-clinical study on diabetic neuropathy

Spinifex Pharmaceuticals, an Australian pain drug development company, today announces the presentation of new data from a study of EMA401 in a model of diabetic neuropathy.

12 Sep 2011

Scientists identify 28 blood pressure-associated genetic variants

A new report from scientists at Massachusetts General Hospital (MGH) and their colleagues in centers around the world finds that common variants in 28 regions of DNA are associated with blood pressure in human patients.

12 Sep 2011

Blocking type 2 receptor reduces PDA cell growth with the activation of AMPK enzyme

Pancreatic cancer researchers at Thomas Jefferson University have shown, for the first time, that blocking a receptor of a key hormone in the renin-angiotensin system (RAS) reduces cancer cell growth by activating the enzyme AMPK to inhibit fatty acid synthase, the ingredients to support cell division.

11 Aug 2011

Lack of kidney dopamine leads to high blood pressure and shorter life span

The neurotransmitter dopamine is best known for its roles in the brain - in signaling pathways that control movement, motivation, reward, learning and memory.

20 Jul 2011

Sorbent expands $36M Series B financing

Sorbent Therapeutics, a private biopharmaceutical company developing therapies for cardiovascular and renal disorders, announced today that it has expanded the Company's Series B financing from September 2010 by $36 million.

30 Jun 2011

Relypsa initiates dosing in RLY5016 Phase 2b trial for hyperkalemia in diabetic nephropathy and CKD patients

Relypsa, Inc. today announced the start of dosing in a Phase 2b clinical trial of RLY5016 for the treatment of hyperkalemia in patients with diabetic nephropathy and chronic kidney disease (CKD). RLY5016 is a high capacity, non-absorbed, polymer-based potassium binder that is orally administered and has been shown to control serum potassium levels in previous studies.

28 Jun 2011

Study finds high prevalence of diabetic kidney disease in the U.S.

Over the past 2 decades the prevalence of diabetic kidney disease in the U.S. increased in direct proportion to the prevalence of diabetes itself, according to a study in the June 22/29 issue of JAMA.

22 Jun 2011

Concert to advance CTP-499, C-21191 into Phase 2 trials for diabetic nephropathy and spasticity

Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform. CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.

20 Jun 2011

Positive results from Relypsa RLY5016 Phase 2 trial to be presented at American Society of Hypertension meeting

Relypsa, Inc. today announced the presentation of positive results from a Phase 2 clinical trial of the company's lead compound, RLY5016, a non-absorbed oral potassium binder being developed as a treatment for hyperkalemia (elevated serum potassium levels).

23 May 2011

FibroGen announces proof-of-principle for FG-4592 Phase 2 study in hemodialysis patients

FibroGen, Inc., today announced proof-of-principle for oral anemia therapy FG-4592, a hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, in end-stage renal disease patients receiving hemodialysis.

4 May 2011

Confusing research on salt and heart: Study

According to the latest European study, people who ate lots of salt were not more likely to get high blood pressure, and were less likely to die of heart disease than those with a low salt intake. This is contrary to what has been known till date. The U.S. guidelines recommend that Americans consume less than 2,300 milligrams of salt daily - 1,500 mg in certain people who are more at risk for high blood pressure or heart disease.

4 May 2011

Takeda announces EDARBI availability in U.S. pharmacies for hypertension treatment

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that EDARBI, an angiotensin II receptor blocker approved for the treatment of hypertension, or high blood pressure, is now available by prescription for adults in U.S. pharmacies.

15 Apr 2011

Increased levels of plasma renin activity protein may predict major cardiovascular event in high-risk patients

Increased levels of a protein that helps regulate the body's blood pressure may also predict a major cardiovascular event in high-risk patients, according to a study led by St. Michael's Hospital's cardiovascular surgeon Subodh Verma. Measuring the amount of the protein, known as plasma renin activity (PRA), in the blood stream may give doctors another tool to assess a patient's risk and help prevent a heart attack or stroke.

8 Apr 2011

Concert initiates CTP-499 Phase 1 study in patients with diabetic nephropathy

Concert Pharmaceuticals, Inc. today announced it has made significant progress advancing CTP-499, its novel anti-inflammatory, anti-oxidant, and anti-fibrotic agent for diabetic nephropathy and other forms of chronic kidney disease, into clinical development.

29 Mar 2011

Combination therapy may reduce albuminuria in patients with type 2 diabetes: Study

Results from a Phase 2, 8-week dose-ranging study using low doses of atrasentan in patients with diabetic kidney disease were published this week in the Journal of the American Society of Nephrology. The published study results suggest that atrasentan, used in conjunction with renin-angiotensin system inhibitors, may reduce albuminuria (presence of protein in urine) for patients with type 2 diabetes.

5 Mar 2011

Takeda receives FDA approval for EDARBI to treat hypertension in adults

Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., today announced that the U.S. Food and Drug Administration approved EDARBI for the treatment of hypertension, or high blood pressure, in adults.

27 Feb 2011

Common genetic risk factor for heart failure in Caucasians also linked to kidney function

Nearly five million Americans live with heart failure, with as many as 700,000 new cases diagnosed each year. In addition to lifestyle factors, scientists have shown that heart failure has a strong heritable component, but identifying the responsible genes has been a major challenge. Now, new research has identified a common genetic risk factor for heart failure in Caucasians that is also linked to kidney function.

19 Jan 2011